Loading Events

Polycystic Kidney Disease Research – Past, Present & Future: Part I

Polycystic Kidney Disease (PKD) is the most commonly inherited disease that can lead to kidney failure.1  Although first described over 500 years ago, it hasn’t been until recently (roughly the past 40 years), that the field has made significant strides towards understanding the genetic characteristics and the pathophysiology of this disease.2 Scientists and clinicians have discovered the genes responsible, delineated dominant and recessive forms, characterized the high degree of variability in presentation, and made remarkable advances in understanding which clinical, genetic, epigenetic, or environmental factors may contribute to a patient’s risk of progressing towards kidney failure faster than other PKD patients.

Please join us as leading experts, James Calvet, PhD and Arlene Chapman, MD, take us on a journey of the past discoveries, clinical advancements made, and the present state of affairs in the PKD research field with the NephU webinar titled, “Polycystic Kidney Disease Research – Past, Present and Future: Part I.”

  1. Chebib FT, Torres VE. Am J Kidney Dis. 2016;67(5):792–810.
  2. Ong AC et al. Lancet. 2015;385(9981):1993-2002.

*Drs Calvet and Chapman are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Sundar and Hajarnis are employees of OPDC.

You must be logged in to register for this event. Please Log In or Join Now

If you would like to register for the 9:00 pm to 10:00 pm EDT broadcast, please click below:

Featured Speakers
James Calvet

James Calvet, PhD

University Distinguished Professor of Biochemistry & Molecular Biology, & Cancer Biology
    University of Kansas Medical Center, Kansas City, KS*

James Calvet PhD is a University Distinguished Professor of Biochemistry and Molecular Biology, and Cancer Biology at the University of Kansas Medical Center, Kansas City, KS. Dr Calvet received his PhD in Genetics and Cell Biology from the University of Connecticut, Storrs, CT. He is currently the PKD Group Leader in the Cancer Biology Program of the University of Kansas Cancer Center, and the Director of the NIH-U54 Kansas PKD Research and Translation Core Center, one of three centers in the US forming the PKD Research Resource Consortium. The consortium has an emphasis on developing basic and translational research for PKD through its three biomedical research cores and pilot & feasibility grants.

Dr Calvet’s early research uncovered a Ca2+-dependent signal transduction defect in PKD cells that transforms normal cells to PKD cells. His group also led to the discovery that cAMP drives both increased cell proliferation and cyst-filling fluid secretion, the basis for seminal advances in the field of PKD research. His lab had also pioneered studies of PKD1 gene structure and function.

Dr Calvet has served on numerous NIH committees and the editorial board of JASN. In 2011 he was honored with the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease, awarded jointly by the International Society of Nephrology and PKD Foundation.

Arlene Chapman

Arlene Chapman, MD

Chief Department of Medicine, Nephrology, Professor of Medicine, Nephrology
    University of Chicago*

Dr Chapman is the section Chief of Nephrology at the University of Chicago and the Director of the Clinical Research Center for the University of Chicago’s Institute for Translational Medicine.

Dr Chapman attended medical school at MacMaster School of Medicine in Ontario, Canada, followed by training in Internal Medicine at Georgetown University School of Medicine in Washington, DC and a fellowship in Renal Medicine at the University of Colorado School of Medicine. She joined the University of Colorado faculty as an Assistant Professor and was later promoted to Associate Professor. She then joined the faculty at Emory University, where she was promoted to Professor of Medicine and later accepted the role of section chief of Nephrology at the University of Chicago.

Dr Chapman’s research focuses on mechanisms of cyst formation in autosomal dominant polycystic kidney disease. She has been integrally involved in the development of novel imaging biomarkers for this disease. In addition, her career has focused on other rare conditions including ARPKD, the CAKUT disorders, ciliopathies, tuberous sclerosis complex and von Hippel Lindau disease.
Her academic contributions include membership on several NIH committees as well as the Scientific Advisory Council for the Polycystic Kidney Disease Research Foundation and the Council for the American Kidney Societies. She has also served on the editorial boards for JASN, CJASN, AJKD, Kidney International, and NDT.

Shirin Sundar

Shirin Sundar, PhD

Nephrology Senior Clinical & Scientific Liaison
Sachin Hajarnis

Sachin Hajarnis, PhD

Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sachin Hajarnis, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.



Join Today for Instant Access to all NephU Offerings.

Membership is free!

Join NephU today at no cost to register for this event and access to other premium content.

  • The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
  • Quickly learn more about the topics that interest you.
  • Access our library of on-demand kidney health resources
  • Gain key insights from industry experts & though leaders.